| Dapagliflozin: more than just another oral glucose-lowering agent? | |
| | |
MedLine Citation:
|
PMID: 21105857 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: With current hypoglycemic therapies, only half of type 2 diabetes mellitus (T2DM) patients achieve optimal glycemic control and even fewer maintain it. Therefore, there is an unmet need for novel antidiabetic agents. Dapagliflozin, a selective inhibitor of sodium glucose transporter 2 (SGLT2), targets hyperglycemia independently of insulin, via decreasing renal glucose reabsorption. AREAS COVERED IN THIS REVIEW: We critically assess the results of up-to-date clinical trials with dapagliflozin in patients with T2DM and discuss its potential therapeutic applications. WHAT THE READER WILL GAIN: Dapagliflozin, apart from targeting hyperglycemia, also exerts beneficial effects on blood pressure, lipid profile, body weight and waist circumference. Furthermore, serum uric acid and high sensitivity C-reactive protein levels were decreased in dapagliflozin-treated patients. However, there are also potentially negative effects related to dapagliflozin use that need to be addressed, such as increased hematocrit and serum parathyroid levels and the possibility of a higher rate of urinary tract and genital infections. TAKE HOME MESSAGE: The use of dapagliflozin in the treatment of T2DM patients seems promising but more evidence is needed. |
| | |
Authors:
|
Niki Katsiki; Nikolaos Papanas; Dimitri P Mikhailidis |
Related Documents
:
|
17619527 - Therapies for diabetes: pramlintide and exenatide. 17211567 - Preprandial repaglinide decreases exogenous insulin requirements and hba1c levels in ty... 17625087 - Tight blood glucose control with insulin in the icu: facts and controversies. 6396097 - Prediction of hyperkalemia associated with prolonged treatment with captopril by glucos... 12857877 - Syntaxin 6 regulates glut4 trafficking in 3t3-l1 adipocytes. 3302077 - Male-factor infertility and in vitro fertilization. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 19 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1581-9 Citation Subset: IM |
Affiliation:
|
Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital campus, University College London Medical School, University College London (UCL), London NW3 2QG, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Therapeutic potential of new second generation antipsychotics for major depressive disorder.
Next Document: Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis - a review of thr...